PCI is pleased to announce a momentous investment in support of biologic medicines and advanced injectable delivery forms, totaling more than $20M. We will add expanded Biotech clinical and commercial packaging and release testing capability at our Center of Excellence in Philadelphia, as well as expanded Cold Chain capacity at numerous global locations to further support our existing Biotech infrastructure.
FUJIFILM Corporation (President: Kenji Sukeno) announced plans to invest approximately JPY 10 billion (approximately $90M U.S. dollars) in order to expand its Bio Contract Development and Manufacturing Organization (CDMO) Business.
Catalent, Inc., the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced it has commenced a $200M capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.
AstraZeneca is recently announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a new phase in its strategic development.
Thousand Oaks Biopharmaceuticals, Inc. (“TOBIO”), a leading integrated global CMC organization including GMP cell culture media and biomanufacturing capabilities recently announced the closing of a $45M USD Series A financing to advance its phase II CDMO and started its construction of Large Scale Cell Culture Media (LSCCM) cGMP Manufacturing facilities based in Haimen, Nantong (part of greater Shanghai), China.
Bristol-Myers Squibb Company and Celgene Corporation recently announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74B.
Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced recently that the Company has completed the acquisition of a manufacturing facility from an affiliate of Shire plc.
FUJIFILM Cellular Dynamics, Inc. (FCDI), a US subsidiary of FUJIFILM Corporation (President: Kenji Sukeno) and a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, has announced an investment of about $21M to open a new cGMP-compliant*1 production facility with the goal of industrializing iPS cell manufacturing for regenerative medicine therapies.
Cambrex Corporation, a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, recently announced that it has completed the acquisition of Avista Pharma Solutions (“Avista”), a contract development, manufacturing, and testing organization, from Ampersand Capital Partners.
Novartis recently announced an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest contract development and manufacturing organizations (CDMO) producing cell and gene therapies in Europe.
|
|
|
|
|
|
|
|
|